Top Stock Gainers
The Daily Runners Archive

Catalyst Announced a record customer count for the first half of 2026: 550 customers as of June 30, up 17.8% from 467 at year end 2025, with Hong Kong exchange IPO filing submissions up from 11 to 64. Operating information only, with no revenue or earnings figures in the release.

Not a first-time runner, and that is the story. CRE traded 24,226,368 shares on 2026-03-06, 15,368,384 on 2026-05-04 (+52% close, +101% intraday) and 22,910,131 on 2026-06-16 (+96% intraday, closed +4%), all post-split, against a 52-week range of $1.68 to $14.64. Today was the fourth big move since March on the same float. 65,248,721 shares traded against a 1,102,735 free float, about 59 float rotations, versus a 20-session average of 66,692 shares and 4,245 shares the prior day. Gapped open +137% at $6.09 after a premarket high of $8.2497 at 7:55am ET, made the day high of $8.60 at 10:25am, then held a $5.85-$6.97 range from 11:00am on declining volume and closed $6.81 on a push in the final half hour: 21% off the high but 12% above its own open. It was a hold through the afternoon, not a bleed. Ended the after hours session at $6.14 (-10%) and traded below $5.80 overnight. The 1.10M float traces to a 1-for-12 reverse split effective 2026-02-13, which cut roughly 19.67M Class A shares to about 1.64M to satisfy Nasdaq's $1.00 minimum bid price requirement; today's percentage is NOT split distorted. No offering, ATM, shelf takedown or ratio change on file in the trailing 30 days.

Catalyst Announced a record customer count for the first half of 2026: 550 customers as of June 30, up 17.8% from 467 at year end 2025, with Hong Kong exchange IPO filing submissions up from 11 to 64. Operating information only, with no revenue or earnings figures in the release.

Not a first-time runner, and that is the story. CRE traded 24,226,368 shares on 2026-03-06, 15,368,384 on 2026-05-04 (+52% close, +101% intraday) and 22,910,131 on 2026-06-16 (+96% intraday, closed +4%), all post-split, against a 52-week range of $1.68 to $14.64. Today was the fourth big move since March on the same float. 65,248,721 shares traded against a 1,102,735 free float, about 59 float rotations, versus a 20-session average of 66,692 shares and 4,245 shares the prior day. Gapped open +137% at $6.09 after a premarket high of $8.2497 at 7:55am ET, made the day high of $8.60 at 10:25am, then held a $5.85-$6.97 range from 11:00am on declining volume and closed $6.81 on a push in the final half hour: 21% off the high but 12% above its own open. It was a hold through the afternoon, not a bleed. Ended the after hours session at $6.14 (-10%) and traded below $5.80 overnight. The 1.10M float traces to a 1-for-12 reverse split effective 2026-02-13, which cut roughly 19.67M Class A shares to about 1.64M to satisfy Nasdaq's $1.00 minimum bid price requirement; today's percentage is NOT split distorted. No offering, ATM, shelf takedown or ratio change on file in the trailing 30 days.

Catalyst No dated catalyst. Nothing filed with the SEC since a 2026-08-07 6-K disclosing a Nasdaq notice that the market value of publicly held shares had fallen below the $15,000,000 minimum, and no press release after 2026-08-20.

The real high was $2.68 at 6:15 AM ET in premarket, +486%; the regular session never traded above $1.73 and closed 51% below the premarket top. The regular session was a net down day, opening $1.46 and closing $1.31. 251.3M shares traded against a 672,638 float, about 374 float rotations. Webull reports free float equal to shares outstanding, so 672,638 is at minimum a hard upper bound; stockanalysis.com showed 920.59K, which would still be ~273 rotations. The 2026-08-20 press release announced an ADS ratio change from 1:60 to 1:420 ordinary shares, the same effect as a 1-for-7 reverse ADS split, effective on or about 2026-09-08, and it is the second of 2026 after a 1-for-20 effective 2026-05-11. Today's percentage is NOT split-distorted; the split has not happened. After hours ranged $1.15 to $1.59 and closed the session at $1.19, down 9%, at 19:59:59 ET.

Catalyst No catalyst found. Nothing was filed with the SEC after 2026-08-18 and no press release is dated after 2026-08-14; the move ran on a 692,761-share free float that turned over about 112 times.

Closed 45% off the $3.13 high, which printed at 2:00 PM ET inside regular hours (premarket topped $1.15, after hours $1.88, overnight traded 3 shares). Context on file but unrelated to the day: an 8-K filed 2026-08-18 disclosed two Nasdaq delisting determinations and a $1,057,417.37 notice of default on a senior secured convertible note; a preferred-stock financing of up to $6.0M was terminated by the lead investor on 2026-07-27; Cohen & Company was engaged 2026-06-03 to evaluate alternatives including liquidation and dissolution. A 1-for-25 reverse split was effective 2026-05-29, so the 52-week high of $127.25 is split-adjusted; today's percentage is NOT split-distorted.

Catalyst Shareholders approved RF Acquisition Corp II's business combination with Nanyang Biologics at an August 19 extraordinary general meeting, a roughly $1.5 billion deal expected to list on Nasdaq as NYB.

The regular session was the aftermath, not the event. RFAI closed Thursday 8/20 at $12.73; the 8-K confirming the Nanyang Biologics merger vote landed that evening and the stock printed $140.52 in Thursday's after-hours session at 5:51pm ET, up about 1,004% from the close (Webull M1; TradingView labels the top $150.00 - a 6.7% provider disagreement). It traded near $87 overnight, popped again to $113.69 at 4:00am, then collapsed to $23.24 before the open. Friday opened $40.00, low $35.22 at 12:10, high $73.00 at 15:40 - exactly where Thursday's after-hours session had stopped - closed $58.00, and finished after hours at $40.34, back at the open and -30% from the close. Peak to that print is -71%. The +356% is measured against a Thursday close that was obsolete within minutes of the bell. Mechanism: about 3.96M shares tendered for redemption ahead of the August 19 vote left a free float of 5,468,765 (shares outstanding 8,343,765); a separate 2025 redemption had already removed 6,668,735 shares at about $10.73, leaving $53,530,961 in trust as of 6/30/26. Read directly from the July 13 F-4/A: the exchange ratio is the quotient of $1,500,000,000 by $10.00, up to 158,940,640 PubCo shares are issued, and RFAC public shareholders end up with 5,406,265 shares (4%) absent further redemptions, as little as 575,000 (1%) at maximum redemption.

Catalyst No dated news on the day. Six days earlier, on August 14, Jianzhi filed a 6-K disclosing a registered direct offering of 12,000,000 ADSs at $0.45 for about $5.4M gross, taking ADSs outstanding from 2,408,313 to 14,408,313.

Spike and fade. The $5.46 high (+221%) printed about fifteen minutes after the open; the $2.023 low came at 12:40 PM ET; it closed $3.32 (+95%), 39% off the high, then fell another 33% after hours to $2.211. Peak to trough was 63%. Volume of 40.6M was roughly 378x the 20-day average near 107K and about 2.8x the entire post-offering ADS count. A 1-for-50 ADS ratio change took effect July 6, 2026, which is why the 52-week high reads $98.40. Float not verifiable as of the runner date given the offering had just closed.

Catalyst Moderna and Merck's personalized mRNA cancer vaccine hit its Phase 3 melanoma primary endpoint, the first mRNA cancer vaccine to succeed in a Phase 3 trial.

Binary-event news gap. Gapped about +84% at the open and ran another roughly +50% intraday. This was a large-cap on hard clinical data, not a small-cap squeeze.

Catalyst A reverse split took effect the same session Profusa reported earnings. The move was a nano-float squeeze on the split, not a fundamental re-rating.

The +506% headline compares the close to an unadjusted $4.53 prior close. A reverse split took effect this session, so the split-adjusted underlying gain was far smaller, roughly +50%. Nano-cap around $7M with a float near 253K shares. Faded to about $13.57 the following session.

Catalyst Low-float pre-market momentum tied to crypto-linked interest, with no hard fundamental catalyst.

Thin float, pre-market driven. Closed off the $9.66 intraday high.

Catalyst Unveiled its Orchestra AI hub, though the run rode a thin post-reverse-split-vote float and a concurrent capital raise.

A capital raise and reverse-split vote were in play, so dilution risk sits under the move. Closed well off the $12.95 high.

Catalyst Q2 2026 earnings: a sharp margin rebound drove a return to profitability and a large earnings beat.

Real fundamental catalyst. Closed off the $19.93 intraday high.

Catalyst Rallied on newly announced capital-raising deals, a thin-float move whose price action diverged from weak fundamentals.

Capital raises are dilutive. Closed off the $9.89 high.

Catalyst No fresh catalyst; a low-float volatile breakout with a cash-rich balance sheet drawing deep-value interest.

Thinly traded breakout; closed off the $12.80 high.

Catalyst No clear catalyst; a low-float pre-market breakout on a thinly traded China e-commerce ADR.

Closed off the $5.17 high.

Catalyst No fresh news; a thin-float China ADR squeeze where daily volume ran past the available share count, the hallmark of forced short covering.

Violent intraday range from $1.33 to $13.97 before closing back near $3.40, a classic squeeze-and-fade.

Catalyst No hard catalyst; a thin-float name with a cash-rich, deep-value balance sheet that tripled intraday and faded.

Ran to $26.17 intraday and closed back at $9.83, a sharp spike-and-fade with no fresh news.

Catalyst Spiked ahead of a critical shareholder vote as a roughly 42% voting stake came into focus, on a thin float.

Corporate-event driven. Thinly traded; closed off the $9.48 high.

Catalyst Won a key cancer-tech patent and released new data, driving a violent move on a small medical-device name.

Real catalyst, but warrant overhang and dilution risk sat under it. Closed off the $24.68 high.

Catalyst A multi-day momentum breakout in a small defense name, with no fresh catalyst on the day itself.

Part of a multi-day run. A Fugazi Research short report called the company uninvestable, citing prior reverse splits and goodwill. Closed off the $70.78 high.

Catalyst Launched new AI software, igniting a trading frenzy on a thin post-reverse-split float.

Warrant dynamics in play (the move cleared an adjusted warrant strike). Closed off the $17.59 high.

Catalyst Ran on growth commentary and new patent wins, alongside a registered direct capital raise.

The registered direct offering is dilutive. Closed off the $6.40 high.

Catalyst Bought a 30% stake in a Taiwan memory firm and struck an AI-energy deal, pivoting toward AI infrastructure.

Deal-driven, then faded off the open. Closed off the $3.98 high.

Catalyst Ran on U.S. market-entry momentum for its Perfecta 3D-printed-meat platform, on a thin float reshaped by a reverse ADS split.

Closed off the $6.30 high.

Catalyst Broke out on anticipation of a Project35 defense agreement, with a reverse split having shrunk the float.

First big day of a multi-day run (also ran on 08-03). A later Fugazi Research short report questioned the company, citing prior reverse splits. Closed off the $15.99 high.

Catalyst An AI power-expansion story met low-float momentum, with daily volume running past four times the share count.

Parabolic squeeze from about $1.20 to $12 intraday. Closed off the high.

Catalyst Jumped on its fiscal Q1 2026 earnings report.

A low-volume earnings move on a higher-priced name (0.8M shares); it edged out the day's higher-volume small-cap runner, $EHGO (+54%). Closed near the $134.93 high.

Catalyst A thin-float spike on heavy volume with no material catalyst, around a routine 6-K and a 13D/A filing.

Ran to $11.96 intraday and closed back near $4.30, a sharp spike-and-fade.

Catalyst Low-float momentum on a thinly traded China EV-retail ADR, with no clearly dated catalyst on the day.

Q2 earnings landed around this window. Closed off the $2.37 high.

Catalyst Ran on reduced dilution risk and an AI-transition pivot, a low-float biotech momentum move.

Closed near the $9.42 high.

Catalyst Surged on a $200M trade-finance facilities announcement for its agri-commodity business.

Ran from a $14.25 prior close to a $30.97 high before closing at $25.30. The financing raised some dilution concerns.

Catalyst An AI power-expansion story collided with low-float momentum to drive the spike.

Ran from $2.13 to a $4.40 high, closing $3.58. Same thin-float name that ran again later in July.

Catalyst Ran on a $3.1M warrant-exercise financing, with a thin float rotating heavily to amplify the move.

Volume topped 176M — many times the float — as the stock spiked to $2.63 before closing $2.07. The warrant exercise carries dilution risk. SOBR makes transdermal alcohol-detection devices.

Catalyst Skyrocketed on an Avere reverse-merger deal paired with a $320M financing plan.

Gapped 4x to a $9.90 high then faded hard, closing at $6.58 — well off the top. The $320M financing carries dilution risk.

Catalyst Announced a merger with USFM Corporation and a pivot into critical minerals, spinning the boat business off into a private company.

First leg of a multi-day run — gapped from $4.82 and ran to a $36.07 high, closing $24.86. Continued higher on July 14 and 16.

Catalyst A 1-for-50 reverse split created a razor-thin float that ignited a momentum run; no fresh fundamental news.

Traded 138M+ shares, ran to $5.79 then pulled back to close $4.57. The reverse split was done to preserve the Nasdaq listing.

Catalyst Speculative low-float buying drove a 4x-plus intraday spike with no fresh corporate catalyst on the recent IPO.

Ran from $3.72 to a $14.90 high before closing at $12.79 on 80M+ shares.

Catalyst Post-split thin float fueled a sharp momentum rally; no fresh company news drove the move.

Followed a 1-for-18 reverse split effective July 6. Ran to $11.98 intraday, closed $8.49. Nasdaq-compliance risk remained.

Catalyst Second leg of the Cortigent neurotech-merger move, as traders kept bidding the transformed story.

Ran from a $7.00 prior close to a $16.50 high before closing at $13.84 — the follow-through day after the July 2 announcement.

Catalyst Rallied on a CEO-linked ~$400K share purchase and regained Nasdaq compliance, with a tiny float amplifying the move.

Gapped from $1.80 to a $7.74 high on 100M+ shares before closing at $6.80. Thin-float momentum name.

Catalyst Announced a merger agreement with Cortigent, a Vivani Medical subsidiary, pivoting the audio-conferencing company toward neurotech.

Intraday move topped +170% (high $9.62 vs prior close $3.22) before closing at $6.48. Deal also included a Vivani majority stake and a $10-15M raise.

Catalyst The board approved a $1 billion crypto investment plan, pivoting the former TuanChe toward a crypto-treasury strategy and igniting speculative buying.

Parabolic and volatile — ran to $6.33 intraday before collapsing to close at $4.80. Company recently rebranded from TuanChe to Token Cat.